April 9, 2024: Kigali, Rwanda and San Francisco, USA

In a landmark move for global healthcare, Bio Usawa Inc., a pioneering African manufacturer of monoclonal antibodies (MAB), commends the United States government’s reinforced pledge to enhance access to essential medicines worldwide—a commitment that shines a spotlight on Africa’s healthcare needs. The recent update from the White House underscores a significant investment in health security, pandemic preparedness, and broadening the reach of medical countermeasures across the globe, aligning closely with Bio Usawa Inc.’s mission to bridge the healthcare gap in Africa. [The US government’s commitment is detailed here.]

Bio Usawa Inc. acknowledges this initiative as a vital step towards addressing longstanding and emerging health threats, including infectious, non-infectious and autoimmune diseases, by ensuring equitable access to preventive and curative healthcare. The emphasis by the Biden-Harris Administration on strengthening global manufacturing and supply chains particularly resonates with Bio Usawa’s strategy to locally produce high-quality, affordable, lifesaving monoclonal antibodies, fostering a self-sufficient African pharmaceutical landscape.

“Access to healthcare is a fundamental human right,” stated Dr. Menghis Bairu, Co-founder and CEO of Bio Usawa Inc. “Aligned with the United States’ commitment to expanding access to medicines around the world, our initiative is more than just a business venture; it is a call to action to end the injustice where patients die because they cannot afford the cure.”

As Bio Usawa Inc. strives to eliminate barriers to essential healthcare services in Africa, the United States’ commitment offers a beacon of hope and support for local manufacturing initiatives, promising a healthier future for communities across the continent and beyond.